Treatment of patient with ideal LDL-Cholesterol

Enrique Mendoza Pérez

2003, Number s1

<< Back Next >>

Arch Cardiol Mex 2003; 73 (s1)

Treatment of patient with ideal LDL-Cholesterol

Mendoza PE

Full text

How to cite this article

Language: Spanish
References: 7
Page: 98-102
PDF size: 61.93 Kb.

ABSTRACT

Coronary heart disease (CHD) is the leading cause of death worldwide. Low-density lipoprotein-cholesterol (LDL-C) reduction is the cornerstone in both primary and secondary cardiovascular prevention. Use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) has proved to reduce LDL-C levels and major coronary event risks. The benefit on cardiovascular risk reduction is greater as LDL-C lowering is greater. Cardiovascular risk remains unacceptably high, even in patients with on-target LDL-C. This paper presents a review of alternatives for both approach and therapy in patients with on-target LDL-C.

REFERENCES

Roeters van Lennep JE, Westerveld HT, Roeters van Lennep H, Zwinderman AH, Erkelens DW, van del Wall EE: Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Atheroscler Thromb Vasc Biol 2000; 20: 2408-13.
Castelli WP: Colesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 1988; 4(supplA): 5A-10A.
Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Münster Study. Am J Cardiol 1992; 70: 733-7.
Rubbins HB, Robbins SJ, Collins D: Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Ned 1999; 341: 410-8.
The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-7.
Ericsson CG, Hamsten A, Nilsson J, et al: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
Anonymous: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet 2001; 357: 905-10.